Pretreatment anti-thyroid autoantibodies indicate increased risk for thyroid autoimmunity secondary to alemtuzumab: A prospective cohort study

BACKGROUND: Alemtuzumab is approved for the treatment of active relapsing-remitting multiple sclerosis (RRMS). Alemtuzumab-related secondary autoimmune disorders (sAID) are common, with thyroid sAID being the most frequent, and fundamentally affect the risk-benefit ratio. Therefore, biomarkers indic...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:EBioMedicine
Auteurs principaux: Ruck, Tobias, Schulte-Mecklenbeck, Andreas, Pfeuffer, Steffen, Heming, Michael, Klotz, Luisa, Windhagen, Susanne, Kleinschnitz, Christoph, Gross, Catharina C., Wiendl, Heinz, Meuth, Sven G.
Format: Artigo
Langue:Inglês
Publié: Elsevier 2019
Sujets:
Research paper
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC6711888/
https://ncbi.nlm.nih.gov/pubmed/31371192
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ebiom.2019.07.062
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires